SCHEMBL219593

SCHEMBL219593

CC(=O)SC(CNC(=O)OCc1ccccc1)CC(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ABCC3 O15438 1/20 0.46
▸ NR1I2 O75469 1/20 0.46
▸ ABCB11 O95342 1/20 0.46
▸ NR3C1 P04150 1/20 0.46
▸ RARG P13631 1/20 0.46
▸ CNR1 P21554 1/20 0.46
▸ OPRK1 P41145 1/20 0.46
▸ NR1H2 P55055 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ NR1H3 Q13133 1/20 0.46
▸ NR1I3 Q14994 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ SYK P43405 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7040817 0.83 CYP1A2 (0.54) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL223222 0.79 LMNA (0.54) LMNASMN1; SMN2HTTSYKALDH1A1
SCHEMBL2762316 0.78 CTSS (0.43) LMNASMN1; SMN2OPRK1HTTSYK
SCHEMBL18931042 0.78 LMNA (0.53) LMNASMN1; SMN2HTTL3MBTL1CTSS
SCHEMBL11821169 0.78 PPARA (0.49) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19415232 0.75 SYK (0.53) LMNASMN1; SMN2HTTSYKL3MBTL1
SCHEMBL9293928 0.75 LMNA (0.59) LMNASMN1; SMN2HTTSYKALDH1A1
SCHEMBL20530482 0.75 ALDH1A1 (0.54) LMNASMN1; SMN2HTTSYKALDH1A1
SCHEMBL5024359 0.75 HTT (0.54) LMNASMN1; SMN2HTTSYKALDH1A1
SCHEMBL221316 0.74 CA12 (0.51) LMNASMN1; SMN2HTTSYKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088925-B2 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2012-01-03 — — US disclosed
EP-1888567-B1 HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS SANOFI AVENTIS (FR) 2009-12-16 — — EP disclosed
US-20080167346-A1 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2008-07-10 — — US disclosed
EP-1888567-A1 HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS Sanofi-Aventis (FR) 2008-02-20 — — EP disclosed
WO-2006122661-A1 HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS (DE) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167346-A1 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents TFPI, SERPINC1, PLAT LMNA 1704/4885SMN1; SMN2 3949/4885CYP1A2 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback